Skip to main content Help with accessibility Skip to main navigation

Inclisiran

Indication

For treating primary hypercholesterolaemia or mixed dyslipidaemia (NICE TA733)

NICE TA733 - Inclisiran for treating primary hypercholesterolaemia or mixed dyslipidaemia

Approval at LSCMMG pending local LSC position statement

Green

Brand:

Nice TA:

733

Commissioning responsibility:

CCG

PbR excluded:

No

BNF chapter:
Cardiovascular system

Background

Approval at LSCMMG pending local LSC position statement

1.1 Inclisiran is recommended as an option for treating primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia as an adjunct to diet in adults. It is recommended only if:

  • there is a history of any of the following cardiovascular events:

    • acute coronary syndrome (such as myocardial infarction or unstable angina needing hospitalisation)

    • coronary or other arterial revascularisation procedures

    • coronary heart disease

    • ischaemic stroke or

    • peripheral arterial disease, and

     

  • low-density lipoprotein cholesterol (LDL-C) concentrations are persistently 2.6 mmol/l or more, despite maximum tolerated lipid-lowering therapy, that is:

    • maximum tolerated statins with or without other lipid-lowering therapies or,

    • other lipid-lowering therapies when statins are not tolerated or are contraindicated, and

     

  • the company provides inclisiran according to the commercial arrangement

Recommendation

LSCMMG Recommendation:

Green

Reason for decision:

Suitable for initiation in primary care

Supporting documents:

Decisions of Lancashire local decision making groups

Pending
Pending
Pending
Pending
Pending
Pending
Pending
Pending
What do the colours mean?

Last Updated: 18 - Nov - 2021